SCHEMBL4349602

SCHEMBL4349602

COc1cncnc1N1CCNCC1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.40
ALK Q9UM73 2/20 0.38
LATS1 O95835 1/20 0.37
HTR2C P28335 8/20 0.36
HTR2A P28223 7/20 0.36
HTR2B P41595 6/20 0.36
MEN1 O00255 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
KMT2A Q03164 2/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
BRPF1 P55201 2/20 0.35
BRD4 O60885 1/20 0.35
BRD1 O95696 1/20 0.35
BRPF3 Q9ULD4 1/20 0.35
TSHR P16473 1/20 0.35
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26669531 1.00 GSK3B (0.40) GSK3BALKLATS1HTR2CHTR2A
Hydrochloric Acid SCHEMBL26599874 0.99 GSK3B (0.39) GSK3BALKLATS1HTR2CHTR2A
Hydrochloric Acid SCHEMBL26599886 0.99 GSK3B (0.39) GSK3BALKLATS1HTR2CHTR2A
SCHEMBL9206909 0.78 HTR2C (0.51) ALKHTR2CHTR2AHTR2BCYP2C19
SCHEMBL31652127 0.77 CYP1A2 (0.52) MEN1CYP1A2CYP3A4CYP2D6KMT2A
SCHEMBL4344404 0.77 CYP1A2 (0.52) MEN1CYP1A2CYP3A4CYP2D6KMT2A
Hydrochloric Acid SCHEMBL23932492 0.76 CYP1A2 (0.51) MEN1CYP1A2CYP3A4CYP2D6KMT2A
SCHEMBL17884512 0.73 CHRNB2 (0.50) GSK3BLATS1HTR2CHTR2AHTR2B
SCHEMBL7091628 0.72 CHRNB2 (0.53) HTR2BMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL4351559 0.71 KIT (0.46) MEN1CYP1A2CYP3A4CYP2D6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281114-A1 INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION FABRE-KRAMER PHARMACEUTICALS, INC. (US) 2009-11-12 US disclosed
WO-2009137733-A1 INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION FABRE-KRAMER PHARMACEUTICALS, INC. (US) 2009-11-12 WO disclosed
US-5763444-A CENTRAL NERVOUS SYSTEM AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 1998-06-09 US disclosed
EP-0761666-A2 Antidepressant 1-arylalkyl-4-(alkoxypyridinyl)- or 4-(alkoxypyrimidinyl)piperazine derivatives BRISTOL-MYERS SQUIBB COMPANY (US) 1997-03-12 EP disclosed
US-5521188-A Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines BRISTOL-MYERS SQUIBB COMPANY (US) 1996-05-28 US disclosed
US-5434154-A Serotonin agonists BRISTOL-MYERS SQUIBB COMPANY (US) 1995-07-18 US disclosed
EP-0645385-A1 Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines Bristol-Myers Squibb Company (US) 1995-03-29 EP disclosed
EP-0464604-B1 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines BRISTOL MYERS SQUIBB CO (US) 1995-03-29 EP disclosed
EP-0464558-B1 Antimigraine alkoxypyrimidine derivatives BRISTOL MYERS SQUIBB CO (US) 1994-12-28 EP disclosed
US-5300506-A Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines BRISTOL-MYERS SQUIBB COMPANY (US) 1994-04-05 US disclosed
EP-0548813-A1 Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines Bristol-Myers Squibb Company (US) 1993-06-30 EP disclosed
EP-0464604-A2 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines Bristol-Myers Squibb Company (US) 1992-01-08 EP disclosed
EP-0464558-A1 Antimigraine alkoxypyrimidine derivatives Bristol-Myers Squibb Company (US) 1992-01-08 EP disclosed
US-5077293-A Antidepressants BRISTOL-MYERS SQUIBB CO. (US) 1991-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281114-A1 INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION HTR5A, TPH2, IDO2 GSK3B 2737/4885ALK 3107/4885LATS1 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.